FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileGenSight Biologics S.A.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GSGTF
GenSight Biologics S.A. Stock AnalysisComprehensive stock analysis for GenSight Biologics S.A. (GSGTF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisGSGTF
GSGTF
GenSight Biologics S.A.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GSGTF
  1. Home
  2. Stocks
  3. GenSight Biologics S.A.

GenSight Biologics S.A.

🇺🇸GSGTF•OTC

GenSight Biologics S.A.

🇺🇸GSGTF•OTC
Market cap
$36.12M

Your view on GSGTF

Mkt Cap
$36.12M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About GenSight Biologics S.A.

Industry
Biotechnology
Sector
Healthcare
CEO
Laurence Rodriguez
Headquarters
74, rue du Faubourg Saint-Antoine, Paris, FR
Industry
Biotechnology
Sector
Healthcare
CEO
Laurence Rodriguez
Headquarters
74, rue du Faubourg Saint-Antoine, Paris, FR
Description

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.

The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.

Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.

The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for GenSight Biologics S.A.. Starting points for GenSight Biologics S.A.: EPS -$0.07, beta 0.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for GenSight Biologics S.A.. GenSight Biologics S.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for GenSight Biologics S.A.. Trailing twelve-month EPS for GenSight Biologics S.A. stands at -$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for GenSight Biologics S.A.. GenSight Biologics S.A. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold GSGTF12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NEUPNeuphoria Therapeutics Inc.HealthcareNASDAQ$12.7M
NGNENeurogene Inc.HealthcareNASDAQ$350.0M
NICXFNicox S.A.HealthcareOTC$30.9M
NIKINiki BioSolutions, Inc.HealthcareNASDAQ$127,856
NKGNNKGen Biotech, Inc. Common StockHealthcareOTC$2.6M
NKTRNektar TherapeuticsHealthcareNASDAQ$866.4M
NKTXNkarta, Inc.HealthcareNASDAQ$81.3M
NMADNOMAD Power Solutions, Inc.HealthcareNASDAQ$31.6M
NMLSFRestart Life Sciences Corp.HealthcareOTC$3.5M
NMRANeumora Therapeutics, Inc. Common StockHealthcareNASDAQ$63.0M
NMTRQ9 Meters Biopharma, Inc.HealthcareOTC$7,230
NNBPNanobac Pharmaceuticals, IncorporatedHealthcareOTC$24,951
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for GenSight Biologics S.A.. Coverage tracks GenSight Biologics S.A. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of GenSight Biologics S.A.

GSGTF AnalysisWeak
Past
1
Growth
1
Health
1
Profit
0
Value
1